1-1 of 1
Masashi Taki
Close
Sort by
Journal Articles

Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors

Clinical Trials & Observations
Midori Shima, Hideji Hanabusa, Masashi Taki, Tadashi Matsushita, Tetsuji Sato, Katsuyuki Fukutake, Ryu Kasai, Koichiro Yoneyama, Hiroki Yoshida, Keiji Nogami
Journal: Blood Advances
Blood Adv (2017) 1 (22): 1891–1899.
https://doi.org/10.1182/bloodadvances.2017006684
Published: 2017
Includes: Supplemental data